Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

What’s New and What’s Next in Glomerular Disease Care, with Sayna Norouzi, MD

Panelists discuss how treatment approaches for C3 glomerulopathy (C3G) have evolved from nonspecific immunosuppression to targeted complement inhibition, with the recent FDA approval of iptacopan marking a significant advancement in disease management.

Personalizing C3G Treatment: Insights From Experienced Clinicians

Panelists discuss how C3 glomerulopathy (C3G) is triggered by factors like infections or pregnancy that activate the alternative pathway in genetically predisposed individuals, presenting with diverse clinical manifestations that often overlap with other glomerular diseases, making diagnosis challenging without kidney biopsy.

The Cost of Diagnostic Delay of C3G Across Age Groups

C3G Diagnosis: Overlapping Symptoms, Triggers, and Evolving Challenges

Panelists discuss how C3 glomerulopathy is an ultrarare glomerular disease characterized by alternative pathway complement dysregulation, which can be caused by either genetic defects or acquired abnormalities like antibodies against regulatory proteins.

Understanding C3G: Pathophysiology and Genetic Factors

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial. 

FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

Pediatric Nephrologists Reluctant to Offer Kidney Transplant in C3G, IC-MPGN

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

Carla Nester, MD: 12-Month Data Informs Potential of Iptacopan in C3 Glomerulopathy

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.

12-Month APPEAR-C3G Data Highlight Potential of Iptacopan in C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.